TickerHumSide-by-side comparison
Bristol-Myers Squibb vs Eli Lilly and
As of Nov 11, 2026, P/E is 13.8x for Bristol-Myers Squibb vs 46.4x for Eli Lilly and; P/S is 2.5x for Bristol-Myers Squibb vs 15.6x for Eli Lilly and; revenue growth is 4.2% for Bristol-Myers Squibb vs 45.5% for Eli Lilly and; net margin is 18.5% for Bristol-Myers Squibb vs 31.9% for Eli Lilly and.
What stands out
- Eli Lilly and is growing revenue faster: 45.5% vs 4.2% for Bristol-Myers Squibb.
- Bristol-Myers Squibb is cheaper on earnings: 13.8x P/E vs 46.4x for Eli Lilly and.
- Eli Lilly and carries less debt relative to equity: 1.17 vs 1.79 for Bristol-Myers Squibb.
Key metrics
| Metric | BMY | LLY |
|---|---|---|
| Price | $62.32 | $1,430.94 |
| Market cap | $127.39B | $1.35T |
| P/E | 13.8x (#1) | 46.4x (#2) |
| P/S | 2.5x (#1) | 15.6x (#2) |
| Revenue growth | 4.2% (#2) | 45.5% (#1) |
| Operating margin | — | — |
| Net margin | 18.5% (#2) | 31.9% (#1) |
| Debt / equity | 1.79 (#2) | 1.17 (#1) |
| 1-year return | +27.0% (#2) | +40.6% (#1) |
| Research score | 69/100 (#2) | 70/100 (#1) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Bristol-Myers Squibb Company (BMY) — Drug Manufacturers—General
- Eli Lilly and Company (LLY) — Drug Manufacturers—General